Micro RNAs (miRNAs) are small RNAs that play an important role in the negative regulation of gene expression by suppressing protein translation. Animal genomes contain an abundance of small genes that produce regulatory RNAs of ≈22 nucleotides in length. The Ambros laboratory identified the first miRNAs in 1993 while characterizing a genetic locus involved in the control of developmental timing in Caenorhabditis elegans. It has since been shown that these miRNAs are diverse in sequence and expression patterns and are evolutionarily widespread, suggesting that they may participate in a wide range of genetic and regulatory pathways. Since their initial discovery, thousands of articles have been published characterizing miRNA properties, defining their expression, and demonstrating function. miRNAs are initially transcribed as long primary miRNAs that are processed by the RNase III enzyme Drosha to generate stem-loop precursors ≈70 nucleotides in length. Two precursors are exported into the cytoplasm, and subsequently, the cytoplasmic enzyme Dicer cleaves the precursor miRNA to release the mature miRNA. Binding of miRNA to an mRNA with Ago proteins inhibits protein translation. It is estimated that the human genome encodes ≈1500 miRNAs that are thought to regulate >30% of protein-coding genes. Because individual variation of miRNA expression levels influences the expression of myriad miRNA target genes, these processes likely contribute to phenotypic differences and susceptibility to common and complex disorders.

Consistent with the recent surge of studies characterizing the role of miRNAs in cellular function and disease relevance is the study by Ganesan et al in the current issue of Circulation. This interesting study focused on miR-378 and its involvement in repressing cardiomyocyte hypertrophy. The study identified a relevant regulatory pathway, specifically mitogen-activated protein kinase8,9 or specifically miR-378 in the cardiac regulation of apoptosis, ischemic heart disease, and mitochondrial function.10

The findings of Ganesan et al provide an interesting and important mechanistic link between an individual miRNA, a specific signaling pathway, and a complex disease. However, as discussed above, miRNAs are generated through the concerted action of complexes that promote multistep processing and loading of miRNA into silencing complexes, with individual classes of microRNAs differentially controlled through the association of regulatory factors. A growing number of studies suggest that each of these steps serves as potential points of regulation, adding to the complexity of miRNA-dependent gene modulation. Regulation of miRNAs is distinct from transcriptional or posttranslational regulation of proteins in that it modifies not only gene expression but also cellular function. Importantly, because a single miRNA such as miR-378 modulates the expression of many targets simultaneously (Figure), the coregulation of multiple miRNAs could dramatically alter both gene expression and cellular function. This complexity is highlighted by large-scale profiling studies using tissue samples that reveal a somewhat consistent yet complex pattern of miRNA dysregulation in human disease12 and in cardiac hypertrophy.7

In the setting of this complexity, the transcription of tissue- and pathway-specific miRNAs may be directed by the same master regulatory factors controlling miRNA such as with skeletal and cardiac muscle differentiation that may be characterized by the transcriptional activation of muscle-specific genes.14 Although master regulation likely occurs in specific settings, this cannot be assumed on the basis of focused examination of miRNAs, gene expression, or tissue. Seeing a cluster of gene expression changes with a targeted assessment or biased prediction model does not preclude other relevant pathways being operational in complex systems. Simply put, if a relevant pathway or transcript is not studied, it cannot be assumed that changes did not occur.

As discussed, an individual miRNA can target multiple genes, and each protein-coding gene can be regulated by several miRNAs. This complexity is compounded by the fact that many studies are performed with exogenous overexpressing miRNAs, and it is not known, even in combinatorial studies, whether the miRNAs will be additive or redundant in their regulation.15 Although single miRNA–single target studies and large-scale screening studies have become plentiful in the literature, there is a paucity of studies...
examining the combinatorial effect of multiple miRNAs on a single protein. One study that attempted this approach found that AKT1 and ERK2, 2 major kinases in the PI3K and RAS oncogenic pathways, might be codownregulated by 30 miRNAs.16 This study used a combined strategy to analyze the multiple miRNA–protein interactions that regulate cell proliferation in response to epidermal growth factor receptor, an oncogenic pathway highly relevant in breast cancer.16 Such a study provides a more complete view of the combinatorial effort of miRNAs to control a signaling pathway at different levels and could be used for cardiac hypertrophy (Figure).

Highlighting the limitations of individual miRNAs as targets, systematic genetic deletions of miRNAs have revealed grossly abnormal phenotypes in <10% of miRNA-mutant systems, and genetic analyses of miRNAs in mice have revealed relatively minor functions under conditions of homeostasis.17 The paucity of strong loss-of-function miRNA phenotypes might be attributable to compensatory mechanisms that allow the recalibration of protein expression. In addition, there is redundancy among homologous miRNAs within families, or the eventual targeting of individual mRNAs by several miRNAs could possibly mitigate eventual phenotypic expression. Many believe the actions of miRNAs become more notable under conditions of injury or stress.18

The relevance of this balance goes well beyond discussion of an miRNA mechanism phenotype. Therapeutics targeting a specific miRNA to target a specific disease are rapidly being developed.19,20 With the use of knowledge gained from antisense technologies, oligonucleotides targeting miRNAs, known as anti-miRs, are being developed for therapeutic use, as are pharmacologically active synthetic miRNAs or miR mimics/mimetics.19,20 The assumption is that the direct downstream targets of a single miRNA are commonly related genes that function in a comparable cellular process or signaling cascade. This implies that targeting of a single miRNA should result in a dramatic effect as a result of the combinatorial effect of gene expression changes in primarily related downstream targets. Whether this assumption is correct will likely depend on the setting. As discussed, a single miRNA can target many genes and many cells, suggesting that the off-target effects will be more complex compared with many classic therapies.

Do these concerns mean a simple miRNA–mRNA–single phenotype–targeted approach is invalid? Obviously, that is not the case. The majority of the disease-based studies currently in the literature are either single miRNA–few target studies or studies of large-scale screening without mechanism, but the true clinical relevance of both types of data will be realized by studies that meet in the middle, that is, well-done mechanistic...
studies that use combinatorial approaches in relevant models. Given the importance of miRNAs in development, it is not surprising that alteration of miRNA expression is implicated in a variety of human diseases and that this has prompted copious investigation into the mechanism and function of miRNA-mediated repression. However, the mechanisms that govern the regulation of microRNA biogenesis and activity are just beginning to be understood and appreciated. Understanding the relative abundance and specific targeted effects in a variety of model systems and defining them broadly in human disease will be central in revealing the true complex function of miRNAs. Thus, judiciously balancing multitarget and single-target approaches with broader screening methods, modeling, and bioinformatics will ultimately define the role of miRNAs in human cardiovascular disease.

Sources of Funding
This work was partially supported by National Institutes of Health grants PO1 A1078894 (to Dr Freedman) and U54 HL12311 (to Drs Freedman and Tanriverdi).

Disclosures
None.

References

Key Words: Editorials ■ hypertrophy ■ microRNAs ■ myocytes, cardiac
Defining miRNA Targets: Balancing Simplicity With Complexity
Jane E. Freedman and Kahraman Tanriverdi

Circulation. 2013;127:2075-2077; originally published online April 26, 2013;
doi: 10.1161/CIRCULATIONAHA.113.003058
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/127/21/2075

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.
Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints
Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/